ABVC BioPharma Statistics
Total Valuation
ABVC BioPharma has a market cap or net worth of $65.81 million. The enterprise value is $66.94 million.
Important Dates
The last earnings date was Monday, November 3, 2025, before market open.
| Earnings Date | Nov 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ABVC BioPharma has 22.81 million shares outstanding. The number of shares has increased by 70.87% in one year.
| Current Share Class | 22.81M |
| Shares Outstanding | 22.81M |
| Shares Change (YoY) | +70.87% |
| Shares Change (QoQ) | +33.76% |
| Owned by Insiders (%) | 11.84% |
| Owned by Institutions (%) | 1.61% |
| Float | 20.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 61.23 |
| Forward PS | n/a |
| PB Ratio | 5.70 |
| P/TBV Ratio | 5.46 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 83.90 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.63, with a Debt / Equity ratio of 0.10.
| Current Ratio | 0.63 |
| Quick Ratio | 0.45 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.71 |
Financial Efficiency
Return on equity (ROE) is -50.86% and return on invested capital (ROIC) is -24.59%.
| Return on Equity (ROE) | -50.86% |
| Return on Assets (ROA) | -18.36% |
| Return on Invested Capital (ROIC) | -24.59% |
| Return on Capital Employed (ROCE) | -35.68% |
| Revenue Per Employee | $41,996 |
| Profits Per Employee | -$278,179 |
| Employee Count | 19 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ABVC BioPharma has paid $24,154 in taxes.
| Income Tax | 24,154 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +421.70% in the last 52 weeks. The beta is 0.24, so ABVC BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | +421.70% |
| 50-Day Moving Average | 2.92 |
| 200-Day Moving Average | 1.96 |
| Relative Strength Index (RSI) | 48.57 |
| Average Volume (20 Days) | 64,993 |
Short Selling Information
The latest short interest is 428,271, so 1.88% of the outstanding shares have been sold short.
| Short Interest | 428,271 |
| Short Previous Month | 635,557 |
| Short % of Shares Out | 1.88% |
| Short % of Float | 2.14% |
| Short Ratio (days to cover) | 4.07 |
Income Statement
In the last 12 months, ABVC BioPharma had revenue of $797,916 and -$5.29 million in losses. Loss per share was -$0.31.
| Revenue | 797,916 |
| Gross Profit | 797,916 |
| Operating Income | -5.23M |
| Pretax Income | -5.69M |
| Net Income | -5.29M |
| EBITDA | -5.20M |
| EBIT | -5.23M |
| Loss Per Share | -$0.31 |
Full Income StatementBalance Sheet
The company has $257,243 in cash and $1.39 million in debt, giving a net cash position of -$1.13 million or -$0.05 per share.
| Cash & Cash Equivalents | 257,243 |
| Total Debt | 1.39M |
| Net Cash | -1.13M |
| Net Cash Per Share | -$0.05 |
| Equity (Book Value) | 14.49M |
| Book Value Per Share | 0.50 |
| Working Capital | -2.43M |
Full Balance SheetCash Flow
| Operating Cash Flow | -2.38M |
| Capital Expenditures | n/a |
| Free Cash Flow | -2.38M |
| FCF Per Share | -$0.10 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -655.91% |
| Pretax Margin | -713.12% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
